Dare Bioscience

DARE · NASDAQ

$0.689+$0.0207 (+3.10%)TodayMarket closed · Oct 21, 4:04 AM ET

Prev close $0.6683

Latest news

Press releaseOct 19, 8:56 AM ETGlobe Newswire
Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer
Press releaseOct 13, 9:15 AM ETGlobe Newswire
Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities
Press releaseOct 8, 9:15 AM ETGlobe Newswire
Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting
Press releaseSep 28, 8:20 AM ETGlobe Newswire
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
Press releaseSep 14, 8:50 AM ETGlobe Newswire
Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil
Press releaseSep 11, 6:55 AM ETGlobe Newswire
Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand
NewsSep 9, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseAug 31, 8:44 AM ETGlobe Newswire
Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth
Press releaseAug 27, 9:01 AM ETGlobe Newswire
Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series
NewsAug 26, 8:47 AM ET
Daré Bioscience Announces Publication Of Clinical Study Results From Its Proprietary Formulation Of Topical Sildenafil Cream, 3.6%, In Menopause In The Journal Of The Menopause Society; 3.6% Was Well Tolerated Across All Evaluated Doses In The Clinical Study, With Minimal Systemic Exposure
Press releaseAug 26, 8:45 AM ETGlobe Newswire
Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society
NewsAug 14, 1:06 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsAug 13, 5:25 PM ET
Dare Bioscience Reports Q2 2026 Results: Full Earnings Call Transcript
NewsAug 13, 5:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseJun 25, 9:05 AM ETGlobe Newswire
Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment
Press releaseMay 26, 8:00 AM ETGlobe Newswire
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
Press releaseMay 18, 8:00 AM ETGlobe Newswire
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies
NewsMay 15, 8:06 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsMay 14, 5:37 PM ET
Dare Bioscience Q1 2026 Earnings Call: Complete Transcript
NewsMay 14, 5:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsMay 14, 7:11 AM ET
Earnings Scheduled For May 14, 2026
NewsMay 12, 2:21 PM ETVandana Singh
Why Is Nano-Cap Dare Bioscience Stock Trading Higher On Tuesday?
Press releaseMay 12, 8:00 AM ETGlobe Newswire
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
Press releaseMay 7, 8:00 AM ETGlobe Newswire
Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026
Press releaseMar 26, 4:01 PM ETGlobe Newswire
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
NewsMar 26, 7:11 AM ET
Earnings Scheduled For March 26, 2026
Press releaseMar 23, 8:00 AM ETGlobe Newswire
On National Viagra Day, Women Finally Claim Their Turn:
Press releaseMar 20, 8:00 AM ETGlobe Newswire
Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026
NewsMar 17, 5:12 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseMar 16, 8:00 AM ETGlobe Newswire
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth
Press releaseMar 12, 8:00 AM ETGlobe Newswire
Daré Bioscience Participates in Virtual Investor "What This Means" Segment
Press releaseFeb 23, 8:00 AM ETGlobe Newswire
Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
Press releaseFeb 11, 8:00 AM ETGlobe Newswire
Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women
Press releaseDec 10, 8:00 AM ETGlobe Newswire
DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility
Press releaseDec 1, 8:00 AM ETGlobe Newswire
Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization
Press releaseNov 24, 8:00 AM ETGlobe Newswire
Daré Bioscience Receives $3.6 Million in Additional Grant Funding
Press releaseNov 13, 4:01 PM ETGlobe Newswire
Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update
NewsNov 12, 12:03 PM ET
What to Expect from Dare Bioscience's Earnings
Press releaseNov 11, 8:00 AM ETGlobe Newswire
Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women's Sexual Health
Press releaseNov 6, 8:00 AM ETGlobe Newswire
Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025
Press releaseNov 3, 8:00 AM ETGlobe Newswire
Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment
Press releaseOct 6, 8:00 AM ETGlobe Newswire
Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders
Press releaseSep 24, 8:00 AM ETGlobe Newswire
Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research
NewsSep 4, 10:05 AM ETAvi Kapoor
This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
NewsAug 14, 5:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseAug 14, 4:01 PM ETGlobe Newswire
Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer

Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities

Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting

Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection

Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil

Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand

12 Health Care Stocks Moving In Wednesday's After-Market Session

Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth

Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series

Daré Bioscience Announces Publication Of Clinical Study Results From Its Proprietary Formulation Of Topical Sildenafil Cream, 3.6%, In Menopause In The Journal Of The Menopause Society; 3.6% Was Well Tolerated Across All Evaluated Doses In The Clinical Study, With Minimal Systemic Exposure

Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society

12 Health Care Stocks Moving In Friday's Intraday Session

Dare Bioscience Reports Q2 2026 Results: Full Earnings Call Transcript

12 Health Care Stocks Moving In Thursday's After-Market Session

Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies

12 Health Care Stocks Moving In Friday's Pre-Market Session

Dare Bioscience Q1 2026 Earnings Call: Complete Transcript

12 Health Care Stocks Moving In Thursday's After-Market Session

Earnings Scheduled For May 14, 2026

Why Is Nano-Cap Dare Bioscience Stock Trading Higher On Tuesday?

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

Earnings Scheduled For March 26, 2026

On National Viagra Day, Women Finally Claim Their Turn:

Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

Daré Bioscience Participates in Virtual Investor "What This Means" Segment

Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization

Daré Bioscience Receives $3.6 Million in Additional Grant Funding

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

What to Expect from Dare Bioscience's Earnings

Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women's Sexual Health

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment

Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

12 Health Care Stocks Moving In Thursday's After-Market Session

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update